Integrin binding human antibody constant domains-Probing the C-terminal structural loops for grafting the RGD motif

Journal of Biotechnology

Volumn 155, Issue 2, 2011, Pages 193-202

  Traxlmayr, Michael W ^a   Wozniak Knopp, Gordana ^a   Antes, Bernhard ^b   Stadlmayr, Gerhard ^a   Rüker, Florian ^a   Obinger, Christian ^a  

^a UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^b Babraham Research Campus   (Austria)

Author keywords

Antibody engineering; Crystallizable domain; Effector function; Integrin binding; Non CDR loop; Structural loop

Indexed keywords

ANTIBODY ENGINEERING; CRYSTALLIZABLE DOMAIN; EFFECTOR FUNCTION; INTEGRIN BINDING; NON-CDR LOOP; STRUCTURAL LOOPS;

ADHESION; ANTIBODIES; CELL ADHESION; GRAFTING (CHEMICAL); PEPTIDES; THERMODYNAMIC STABILITY;

BINDING SITES;

CD16 ANTIGEN; CRYSTALLIZABLE FRAGMENT OF IMMUNOGLOBULIN G1; HOMODIMER; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; INTEGRIN; PROTEIN A; UNCLASSIFIED DRUG; VITRONECTIN; VITRONECTIN RECEPTOR;

AMINO ACID SEQUENCE; ANTIBODY ENGINEERING; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CELL ADHESION; CELL STRAIN K 562; NONHUMAN; PICHIA PASTORIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; TEMPERATURE; THERMOSTABILITY;

CELL LINE, TUMOR; CLONING, MOLECULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOGLOBULIN CONSTANT REGIONS; IMMUNOGLOBULIN G; INTEGRINS; PICHIA; PROTEIN BINDING; PROTEIN ENGINEERING; RECEPTORS, FC; RECEPTORS, IGG; STAPHYLOCOCCAL PROTEIN A;

PICHIA PASTORIS;

EID: 80051469818     PISSN: 01681656     EISSN: 18734863     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2011.06.042     Document Type: Article

References (35)

1. Baker K., Qiao S.W., Kuo T., Kobayashi K., Yoshida M., Lencer W.I., Blumberg R.S. Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn. Semin. Immunopathol. 2009, 31:223-236.
2. Burmeister W.P., Huber A.H., Bjorkman P.J. Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature 1994, 372:379-383.
3. Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-Å resolution. Biochemistry 1981, 20:2361-2370.
4. Ghirlando R., Lund J., Goodall M., Jefferis R. Glycosylation of human IgG-Fc: influences on structure revealed by differential scanning calorimetry. Immunol. Lett. 1999, 68:47-52.
5. Gurrath M., Muller G., Kessler H., Aumailley M., Timpl R. Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides. Eur. J. Biochem. 1992, 270:911-921.
6. Halaby D.M., Poupon A., Mornin J. The immunoglobulin fold family: sequence analysis and 3D structure comparisons. Protein. Eng. 1999, 12:563-571.
7. Hamilton S.R., Gerngross T.U. Glycosylation engineering in yeast: the advent of fully humanized yeast. Curr. Opin. Biochnol. 2007, 18:387-392.
8. Harmsen M.M., De Haard H.J. Properties, production, and applications of camelid single-domain antibody fragments. Appl. Microbiol. Biotechnol. 2007, 77:13-22.
9. Huang T.F., Holt J.C., Lukasiewicz H., Niewiarowski S. Triramin. A low molecular weight peptide inhibiting fibrinogen interaction with platelet receptors expressed on glycoprotein IIb-IIIa complex. J. Biol. Chem. 1987, 262:16157-16163.
10. Huston J.S., Levinson D., Mudgett-Hunter M., Tai M.-S., Novotny J., Margolies M.N., Ridge R.J., Bruccoleri R.E., Haber E., Crea R., Oppermann H. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Sci. U.S.A. 1988, 85:5870-5883.
11. Imura Y., Stassen J.-M., Bunting S., Stockmans F., Collen D. Antithrombotic properties of l-cysteine, N-(mercaptoacetyl)-d-Tyr-Arg-Gly-Asp-sulfoxide (G4120) in a hamster platelet-rich femoral vein thrombosis model. Blood 1992, 80:1247-1253.
12. Jefferis R., Lund J., Pound J.D. IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation. Immunol. Rev. 1998, 163:59-76.
13. Jefferis R., Lund J. Interaction sites on human IgG-Fc for FcgR: current models. Immunol. Lett. 2002, 82:57-65.
14. Kabsch W., Sander C. Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 1983, 22:2577-2637.
15. 1 integrin from phage display library. J. Biol. Chem. 1993, 268:20205-20210.
16. Krapp, Mimura Y., Jefferis R., Huber R., Sonderman P. Structural analysis of human IgG1-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J. Mol. Biol. 2003, 325:979-989.
17. Kubota T., Niwa R., Satoh M., Akinaga S., Shitara K., Hanai N. Engineered therapeutic antibodies with improved effector functions. Cancer Sci. 2009, 9:1566-1572.
18. Li J., Ji J., Holmes L.M., Burgin K.E., Barton L.B., Yu X., Wagner T.E., Wei Y. Fusion protein from RGD peptide and Fc fragment of mouse immunoglobulin G inhibits angiogenesis in tumor. Cancer Gene Ther. 2004, 11:363-370.
19. Liu H., Bulseco G.-G., Sun J. Effect of posttranslational modifications on the thermal stability of a recombinant monoclonal antibody. Immunol. Lett. 2006, 106:144-153.
20. Lund J., Tanaka T., Takahashi N., Sarmay G., Arata Y., Jefferis R. A protein structural change in aglycosylated IgG3 correlates with loss of huFc gamma R1 and huFc gamma R111 binding and/or activation. Mol. Immunol. 1990, 27:1145-1153.
21. Mimura Y., Church S., Ghirlando R., Ashton P.R., Dong S., Goodall M., Lund J., Jefferis R. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Mol. Immunol. 2000, 37:697-706.
22. Murzin A.G., Brenner S.E., Hubbard T., Chothia C. SCOP: a structural classification of proteins database for the investigation of sequences and structures. J. Mol. Biol. 1995, 247:536-540.
23. Powers D.B., Amersdorfer P., Poul M., Nielsen U.B., Shalaby M.R., Adams G.P., Weiner L.M., Marks J.D. Expression of single-chain Fv-Fc fusions in Pichia pastoris. J. Immunol. Methods 2001, 251:123-135.
24. Raghavan M., Bonagura V.R., Morrison S.L., Bjorkman P.J. Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry 1995, 34:14649-14657.
25. Riddles P.W., Blakeley R.L., Zerner B. Ellman's Reagent: 5,5'-dithiobis(2-nitrobenzoic Acid) - a reexamination. Anal. Biochem. 1979, 94:75-81.
26. Riener C.K., Kada G., Gruber H.J. Quick measurement of protein sulfhydryls with Ellmanós reagent and with 4,4'-dithiodipyridine. Anal. Bioanal. Chem. 2002, 373:266-276.
27. Rüker F., Wozniak-Knopp G. Engineering of non-CDR loops in immunoglobulin domains. Recombinant Antibodies for Immunotherapy Part VI 2009, 231-242. Cambridge University Press, New York. M. Little (Ed.).
28. Silverman A.P., Levin A.M., Lahti J.L., Cochran J.R. Engineered cystine-knot peptides that bind alpha(v)beta(3) integrin with antibody-like affinities. J. Mol. Biol. 2009, 385:1064-1075.
29. Skerra A., Plückthun A. Assembly of a functional Fv fragment in Escherichia coli. Science 1988, 240:1038-1041.
30. Sondermann P., Huber R., Oosthuizen V., Jacob U. The 3.2Å crystal structure of the human IgG1 Fc fragment-FcγRIII complex. Nature 2000, 406:267-273.
31. Tischenko V.M., Abramov V.M., Zav'yalov V.P. Investigation of the cooperative structure of Fc fragments from myeloma immunoglobulin G. Biochemistry 1998, 37:5576-5581.
32. Wozniak-Knopp G., Bartl S., Bauer A., Mostageer M., Woisetschläger M., Antes B., Ettl K., Kainer M., Weberhofer G., Wiederkum S., Himmler G., Mudde G.C., Rüker F. Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties. Protein Eng. Des. Sel. 2010, 1-9.
33. Xiao X., Feng Y., Vu B.K., Ishima R., Dimitrov D.S. A large library based on a novel (CH2) scaffold: identification of HIV-1 inhibitors. Biochem. Biophys. Res. Commun. 2009, 387:387-392.
34. Xiao J., Chen R., Pawlicki M.A., Tolbert T.J. Targeting a homogeneously glycosylated antibody Fc to bind cancer cells using a synthetic receptor ligand. J. Am. Chem. Soc. 2009, 131:13616-13618.
35. Zheng X.X., Steele A.W., Hancock W.W., Kawamoto K., Li X.C., Nickerson P.W., Li Y., Tian Y., Strom T.B. IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice. J. Immunol. 1999, 163:4041-4048.